CliffBio
biologic

Kcentra

Prothrombin Complex Concentrate (Human)

Loss of exclusivityApril 2025projected — 12-year biologic exclusivity estimate
CompanyCSL Behring →See this company's full patent-cliff portfolio

Drug detail

Brand nameKcentra
Active ingredientProthrombin Complex Concentrate (Human)
Strength500IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalApril 2013
Marketing statusRx

More from CSL Behring

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Kcentra patent cliff — loss of exclusivity April 2025 | CliffBio